trending Market Intelligence /marketintelligence/en/news-insights/trending/3VoEqvJwrorUGg-QZY3O5Q2 content esgSubNav
In This List

Summa Equity buys majority stake in Olink Proteomics

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Banking Essentials Newsletter: 7th February Edition

Case Study

A Bank Outsources Data Gathering to Meet Basel III Regulations

Podcast

Private Markets 360° | Episode 8: Powering the Global Private Markets (with Adam Kansler of S&P Global Market Intelligence)


Summa Equity buys majority stake in Olink Proteomics

Summa Equity purchased Sweden-headquartered life sciences company Olink Proteomics AB, which has developed technology for human biomarker discovery.

Under the deal, the private equity firm will become the company's majority shareholder, while its founder Ulf Landegren and the management team will continue as stockholders.

Moelis & Co. LLC served as financial adviser to Summa, White & Case was its legal adviser, LEK Consulting was its commercial adviser and KPMG was its accounting adviser. J.P. Morgan Securities LLC acted as financial adviser to Olink, while Wiggin, Dana LLP and Lindahl were its legal advisers.